| scholarly article | Q13442814 |
| P2093 | author name string | Hector RF | |
| Yee E | |||
| P2860 | cites work | Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome | Q33441514 |
| Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis | Q33737820 | ||
| Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole | Q34055524 | ||
| Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis | Q35295703 | ||
| Adrenal response to corticotropin during therapy with itraconazole | Q35539308 | ||
| Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice | Q35648045 | ||
| Mammary gland contamination as a means of establishing long-term gastrointestinal colonization of infant mice with Candida albicans | Q36338220 | ||
| Recent advances in the treatment of systemic fungal infections. | Q39202202 | ||
| Itraconazole in the treatment of human mycoses: review of three years of clinical experience | Q39507028 | ||
| The epidemiology of AIDS in the U.S. | Q39572509 | ||
| Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice | Q39814888 | ||
| Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans | Q39817645 | ||
| Fluconazole and testosterone: in vivo and in vitro studies. | Q39818132 | ||
| Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits | Q39851052 | ||
| Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome | Q41843686 | ||
| Itraconazole treatment of experimental systemic candidiasis in male rats | Q42113523 | ||
| Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans | Q44368175 | ||
| A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit | Q44655286 | ||
| Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. | Q51803060 | ||
| Itraconazole: pharmacologic studies in animals and humans. | Q53883577 | ||
| Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. | Q54121244 | ||
| Itraconazole in the treatment of acute vaginal candidiasis. | Q54127393 | ||
| R 51211 (itraconazole) therapy of murine cryptococcosis. | Q54485729 | ||
| Cryptococcal meningitis in patients with AIDS | Q68128522 | ||
| Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system | Q69814579 | ||
| Pharmacokinetic profile of orally administered itraconazole in human skin | Q69820417 | ||
| Fluconazole penetration into cerebrospinal fluid in humans | Q69832022 | ||
| Itraconazole treatment of murine aspergillosis | Q70094463 | ||
| Treatment of cryptococcal meningitis in mice with fluconazole | Q70148103 | ||
| Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report | Q70163495 | ||
| A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis | Q70163498 | ||
| Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results | Q70163502 | ||
| Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole | Q70163506 | ||
| Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals | Q72140760 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| candidiasis | Q273510 | ||
| cryptococcosis | Q1470140 | ||
| P304 | page(s) | 448-454 | |
| P577 | publication date | 1990-03-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis | |
| P478 | volume | 34 |
| Q36882122 | Antifungal chemotherapy — Are we winning? |
| Q41740968 | Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development |
| Q28379262 | Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis |
| Q28367767 | Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis |
| Q28379259 | In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum |
| Q28316952 | In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin |
| Q35821534 | Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma |
| Q28316948 | Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo |
| Q39866778 | Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients |
| Q28379379 | T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations |
| Q35098130 | Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion |
| Q36981602 | Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis |
Search more.